Home » Archive by Category


San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Volunteers Can Now Help Seek Ebola Cure in Their (Computer’s) Spare Time

December 8, 2014 – 1:00 am | Edit Post

Free virtual supercomputer power from IBM’s cloud-enabled World Community Grid will power screening of promising drug compounds by the Ollmann Saphire lab.

Fate Therapeutics Unveils Preclinical Findings Of Newly-Identified Small Molecule Modulator Combination For Ex Vivo Programming Of Mobilized Peripheral Blood

December 7, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 6, 2014 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, released preclinical data today highlighting the pharmacological properties of ex vivo…

ACADIA Pharmaceuticals, Inc. Presents Caregiver Burden Data At The International Congress Of Non-Motor Dysfunctions In Parkinson???s Disease And Related Disorders

December 7, 2014 – 5:00 pm | Edit Post

Data Demonstrate a Decreased Burden Among Caregivers of Patients with Parkinsons Disease Psychosis Treated with NUPLAZID (Pimavanserin) SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ…

Vital Therapies, Inc. (VTI) Announces First Subject Enrolled In VTI-210 And Provides Update On Enrollment In VTI-208

December 7, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 8, 2014 (GLOBE NEWSWIRE) — Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD, a cell-based therapy targeting treatment of acute liver failure, today announced enrollment of the first subject in its Phase 3 trial in severe acute alcoholic hepatitis (AAH) designated…

Organovo Appoints To Board Of Directors

December 7, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 8, 2014 /PRNewswire/ — Organovo Holdings, Inc. (NYSE MKT: ONVO) (“Organovo”), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, announced todayKirk D. Malloy, Ph.D. has been appointed to the Company’s Board of Directors. Dr. Malloy has held management…

OncoSec Medical Inc. Announces First Quarter Results For Fiscal Year End 2015

December 7, 2014 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the quarter ended October 31, 2014.FINANCIAL RESULTSFor the quarter ended October 31, 2014, OncoSec Medical reported a net loss of $4.1 million, or $0.02 per share, compared to a net loss of $2.1 million, or…

Isis Pharmaceuticals, Inc. Reports Positive Phase 2 Data For ISIS-FXI Rx For The Prevention Of Venous Thrombosis In Patients Undergoing Total Knee Replacement Surgery

December 7, 2014 – 5:00 pm | Edit Post

Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgerydiv class”xn-content”>CARLSBAD, Calif., Dec. 7, 2014 /PRNewswire/ — Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today final data…

Geneva Healthcare Begins System-Wide Implementation At <b>Sharp HealthCare</b>

December 7, 2014 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Geneva Healthcare today announced that Sharp HealthCare will begin using The Geneva Healthcare Suite, an innovative technology platform for managing data from cardiac devices, in all four of its emergency departments at its acute care hospitals. The platform will be used to access and organize cardiac device data from every patient who arrives at the emergency department…

Qualcomm Announces Collaboration With <b>Vitaphone E-Health Solutions</b> To Power High-Tech, High-Touch Telehealth And Remote Monitoring Services

December 7, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 8, 2014 /PRNewswire/ –Qualcomm Incorporated (NASDAQ: QCOM) today announced that its subsidiary, Qualcomm Life, Inc., is collaborating with vitaphone e-health solutions, a global full service provider of care management…

Triphase Accelerator Announces Its Proteasome Inhibitor Marizomib Demonstrates Potent Synergistic Anti-Multiple Myeloma Activity In Combination With Pomalidomide

December 7, 2014 – 5:00 pm | Edit Post

TORONTO & SAN DIEGO–(BUSINESS WIRE)–Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase II proof-of-concept, today announced preclinical study results demonstrating that the combination of its highly differentiated proteasome inhibitor marizomib and pomalidomide (Pomalyst) was synergistic in killing multiple myeloma cells. Combined…